DIA413.88+2.83 0.69%
SPX5,663.94+32.66 0.58%
IXIC17,928.14+189.98 1.07%

Sharps Technology Receives $400K Purchase Order From U.S. Leader In IV Flushing Solutions

Benzinga·04/30/2025 11:02:38
Listen to the news

Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreement

Investments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production to meet long-term contract demand

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced the receipt of a $400,000 purchase order from a U.S. leader in IV flushing solutions. This marks the first order under the previously announced $50 million supply agreement from July 2024.

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.